Systematic Patent Review of Nanoparticles in Drug Delivery and Cancer Therapy in the Last Decade

Hazis, Nur Umairah Ali; Aneja, Nagender; Rajabalaya, Rajan; David, Sheba R

doi:10.2174/1872211314666210521105534

Cited by 8 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metallic NPs have been evaluated as diagnostic and therapeutic molecules. Currently, however, only a few technologies based on metallic NPs have been approved by the FDA for diagnostic and therapeutic use [ 15 ]. For example, the nanodrug, Aurimune (CYT-6091), was produced by linking AuNPs to recombinant human tumor necrosis factor-α (rhTNF-α) and PEG [ 170 ].…”

Section: Various Classes Of Nanomedicinesmentioning

confidence: 99%

“…Another patent (WO 2014/047318) for drug delivery, invented by Kaittanis et al. [ 15 ] is based on iron oxide NPs [ 173 ]. In breast cancer patients, superparamagnetic iron oxide nanoparticles (SPION) accumulate in the sentinel lymph nodes (SLN).…”

Section: Various Classes Of Nanomedicinesmentioning

confidence: 99%

“…The delivery of anticancer drugs can be achieved by various routes of administration. The choice of the route of administration by a clinician depends on various factors, including but not limited to, the drug, type of cancer, efficacy, location of the tumor in the body, and toxicity of the drug, among others [ 15 ], [ 16 ], [ 17 ], [ 18 ]. Furthermore, certain anticancer drugs can be administered directly into the tumor [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Nanotechnology-based delivery systems to overcome drug resistance in cancer

Patel,

Li,

et al. 2024

Medical Review

View full text Add to dashboard Cite

Cancer nanomedicine is defined as the application of nanotechnology and nanomaterials for the formulation of cancer therapeutics that can overcome the impediments and restrictions of traditional chemotherapeutics. Multidrug resistance (MDR) in cancer cells can be defined as a decrease or abrogation in the efficacy of anticancer drugs that have different molecular structures and mechanisms of action and is one of the primary causes of therapeutic failure. There have been successes in the development of cancer nanomedicine to overcome MDR; however, relatively few of these formulations have been approved by the United States Food and Drug Administration for the treatment of cancer. This is primarily due to the paucity of knowledge about nanotechnology and the fundamental biology of cancer cells. Here, we discuss the advances, types of nanomedicines, and the challenges regarding the translation of in vitro to in vivo results and their relevance to effective therapies.

show abstract

Section: Various Classes Of Nanomedicinesmentioning

confidence: 99%

Section: Various Classes Of Nanomedicinesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanotechnology-based delivery systems to overcome drug resistance in cancer

Patel,

Li,

et al. 2024

Medical Review

View full text Add to dashboard Cite

show abstract

“…With advantages such as small size, high penetration and better targeting of cancer cells, the number of patented technologies for nanomaterial-based drug delivery systems continues to grow. 163 Many different types of nanomaterials have been patented for drug delivery, including metal, carbon, silica, lipid, and polymeric nanomaterials. Patent WO2014047318Al for targeted combination therapy of cancer attaches therapeutic agents to iron oxide nanomaterials with superparamagnetic properties in a noncovalent manner, thereby maintaining the original structure and function of the drug, and it also significantly improves the bioavailability and stability of the loading agent.…”

Section: Patents Related To Nanomaterial-based Drug Delivery Systemsmentioning

confidence: 99%

Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy

Jiang¹,

Zhang²,

Zhang³

et al. 2022

IJN

View full text Add to dashboard Cite

Cancer immunotherapy, a major breakthrough in cancer treatment, has been successfully applied to treat a number of tumors. However, given the presence of factors in the tumor microenvironment (TME) that impede immunotherapy, only a small proportion of patients achieve a good clinical response. With the ability to increase permeability and cross biological barriers, nanomaterials have been successfully applied to deliver immunotherapeutic agents, thus realizing the anti-cancer therapeutic potential of therapeutic agents. This has driven a wave of research into systems for the delivery of immunotherapeutic agents, which has resulted in widespread interest in nanomaterial-based drug delivery systems. Nanomaterial-based drug delivery systems are able to overcome the challenges from TME and thus achieve good results in cancer immunotherapy. If it can make a breakthrough in improving biocompatibility and reducing cytotoxicity, it will be more widely used in clinical practice. Different types of nanomaterials may also have some subtle differences in enhancing cancer immunotherapy. Moreover, delivery systems made of nanomaterials loaded with drugs, such as cytotoxic drugs, cytokines, and adjuvants, could be used for cancer immunotherapy because they avoid the toxicity and side effects associated with these drugs, thereby enabling their reuse. Therefore, further insights into nanomaterial-based drug delivery systems will provide more effective treatment options for cancer patients.

show abstract